{
  "outcomes_metadata": {
    "timestamp": "2025-10-04T14:14:06.818612",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 43,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "prolonged survival",
        "event-free survival",
        "progression-free survival (PFS)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (RECIST v1.1)",
        "progression-free survival (independent review committee, RECIST 1.1)",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival",
        "time to progression (TTP)",
        "time to progression"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "overall response rate",
        "response rate",
        "disease control rate",
        "disease control rate (DCR)",
        "duration of response",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response",
        "treatment duration",
        "duration of treatment",
        "time to next treatment (TTNT)",
        "time to next treatment"
      ],
      "progression_measures": [
        "treatment discontinuation due to adverse events (CTCAE v5.0)",
        "treatment discontinuation due to adverse events (CTCAE v4.03)",
        "dropout rate"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events (general; CTCAE v5.0)",
        "adverse drug reactions",
        "adverse effects that affect health-related quality of life",
        "side effects",
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects",
        "serious side effects on the skin",
        "mortality-related toxicity",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects",
        "serious side effects on the skin",
        "mortality-related toxicity"
      ],
      "discontinuations": [
        "treatment discontinuation due to adverse events (CTCAE v5.0)",
        "treatment discontinuation due to adverse events (CTCAE v4.03)",
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "health status",
        "overall health status",
        "health-related quality of life",
        "health-related quality of life (measured by time to death)",
        "quality of life",
        "preservation of quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment",
        "treatment-related disutility for intravenous administration"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}